Novo Nordisk's blockbuster drugs Ozempic and Wegovy have slimmed down Hollywood stars and millions of non-celebrities ...

This week, 60 Minutes traveled to Denmark to report on Novo Nordisk, the pharmaceutical company that's behind the popular ...

Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked ...

Drugs Ozempic and Wegovy have slimmed down Hollywood stars — and millions of non-celebrities worldwide— while adding great ...

Novo Nordisk's (NVO) semaglutide, marketed as Wegovy for obesity, shows promise in reducing joint disease symptoms in ...

NVO's third-quarter revenues are expected to have been driven by its diabetes and obesity care product sales, especially Wegovy, Ozempic and Rybelsus.

Novo Nordisk acquires exclusive worldwide license to Ascendis Pharma’s TransCon technology for developing metabolic and ...

Novo Nordisk is scheduled to report results for the third quarter on Wednesday. Here is what you need to know: NET PROFIT FORECAST: Net profit in the quarter is expected to rise 19% to 26.79 billion ...

In a deal worth up to $285 million initially for the lead program, Novo Nordisk will gain access to Ascendis’ TransCon ...

Ascendis Pharma (ASND) has released an update. Ascendis Pharma has entered a collaboration with Novo Nordisk to license its TransCon ...

Novo Nordisk A/S’s Wegovy helped treat an obesity-associated liver disease in a late-stage trial, potentially adding to its ...